Prescription conversation
Agree on decisions together
The 2023 international guideline emphasises shared decision making, emotional wellbeing, quality of life and attention to weight stigma. Care should make room for your preferences and priorities.
Symptom guide · Bleeding, Bladder, Pelvic & Hormone Conditions · Evidence-graded
PMOS care in midlife. Your history, your current priorities.
Changes in periods, hair or skin can make an existing care routine feel less suited to your life. Questions about sleep, mood or test results may add to the work of keeping track of your health.
Your review can include the concerns that matter to you beyond periods or fertility.
What you might notice
Changes from your usual pattern may raise questions about your existing care.
Worth considering
Bring your history, medicines and current priorities without assuming a fixed midlife course.
A starting point
Ask for an individual review that includes sleep, emotional wellbeing and metabolic health.
Start with what you've noticed and your own health history. Find guides for your body →
Search stays on this device
Use your own history to guide the conversation, rather than expecting a fixed midlife pattern.
PMOS care can include more than cycle or fertility questions. The 2023 international guideline recognises metabolic, cardiovascular, sleep and psychological concerns, and emphasises shared decisions. Its authors also note that the evidence remains generally low to moderate quality; it does not justify a single predicted course through perimenopause.
The 2023 international PMOS guideline strengthens recognition of metabolic risk factors, cardiovascular disease, sleep apnea and psychological concerns as part of the condition. These are topics for individual assessment, not a prediction that you will develop each problem.
The 2023 guideline describes the evidence for assessment and management as generally low to moderate quality. Ask which recommendations apply to your age, symptoms and medical history.
Bring questions about cycle changes, hair or skin concerns, mood and concentration. Ask for assessment of new symptoms without presuming their cause.
You don't have to make the disruption look smaller to ask for help.
PMOS in perimenopause has a small set of red flags that always deserve prompt clinical attention.
Ask for assessment of heavy or prolonged bleeding after a gap. Your history guides any imaging or other tests; heavy bleeding with fainting or breathing difficulty needs emergency help.
Postmenopausal bleeding in someone with a PMOS history needs urgent gynecological assessment. Usually benign; occasionally not.
Ask your clinician to explain the results and discuss an individual prevention or treatment plan. A fixed combination of medicines, diet and exercise is not appropriate for everyone.
Bring repeated blood-pressure readings to a review and ask what assessment or treatment fits. Your age or PMOS history cannot predict a fixed course or establish hypertension by itself.
Mention snoring, gasping or unrefreshing sleep and ask whether a sleep assessment would help alongside your other care.
Stays on this device. It isn't sent to your account, Nila or anyone else. Three days describe what you noticed, not a diagnosis.
0 of 3 days logged.
Keep the notes you find useful; ask your clinician what measurements they need.
Record dates, duration and your description of flow, including changes from your usual pattern. Bring concerns about changed bleeding to a clinician.
Keep copies of test results and the agreed date for review. If home blood-pressure readings are requested, ask how and when to take them.
Note what you experience, when it happens and what you want help with, without needing to assign a cause.
List which symptoms matter most to you, what you have tried and what you would like to discuss next.
Options, not a to-do list.
Build a plan around your priorities and ask how it will be reviewed.
Prescription conversation
The 2023 international guideline emphasises shared decision making, emotional wellbeing, quality of life and attention to weight stigma. Care should make room for your preferences and priorities.
Comfort
Comfort
Bring a list of prescriptions and supplements. Ask about the reasons for each, alternatives, monitoring and whether your menopause questions need a separate assessment.
Comfort
Take this to your appointment.
Track a few days above to fill this in — or use the questions below as-is.
Pick an option in What tends to help above to add it here.
“These are interrupting ___. Would an examination or test help? What would it tell us, and what could we do without it?”
“Which option would you suggest for me, and what side effects or checks should I expect?”
“What should I notice after starting treatment, and when will we check in?”
Ask what any proposed test would help decide, who will explain the results, and when to return.
Same symptom, different doors.
Grades describe the recorded source type. A source listed here doesn't automatically support every sentence or every treatment.
Hum Reprod · 2023
Munro et al · FIGO Menstrual Disorders Working Group · 2011
The FIGO PALM-COEIN classification includes fibroids among causes of abnormal uterine bleeding in non-pregnant people of reproductive age. More than one cause may coexist; it is a communication and assessment framework, not a symptom-based diagnosis.
NICE · 2021
UK heavy-menstrual-bleeding guidance considers symptoms, daily-life impact, preferences and fibroid size, number and location when choosing investigations and care. It describes medicines and procedures, with treatment suitability depending on the findings. Local access and prescribing can differ.
SOGC Clinical Practice Guideline · J Obstet Gynaecol Can · 2018
Canadian guideline on assessment and management of abnormal bleeding before menopause, including when imaging or endometrial sampling is warranted.
Wilding et al · New England Journal of Medicine · 2021
Industry-funded (Novo Nordisk) trial. Average weight loss about 15% over 68 weeks; part of the loss was lean mass.
Gravelsins et al · Science · 2026
Review mapping estrogen and progestogen receptors across organs, including this one. Narrative review, not a trial.
NHS · Official care guidance
Official care guidance for the linked warning: when to seek assessment or urgent help. This is not evidence of a menopause-specific cause or treatment.
North American Menopause Society (NAMS) · 2022
International Menopause Society (IMS) · 2024
NICE (UK National Institute for Health and Care Excellence) · 2024
Endocrine Society · 2015
Society of Obstetricians and Gynaecologists of Canada (SOGC) · 2024
SOGC's public-facing menopause resource, the Canadian counterpart to NAMS patient education.
Canadian Menopause Society · 2024
Canada's specialist society for menopause practitioners (formerly SIGMA); referenced by SOGC.
Ashlene Korcek, MS, LMHC
One of the few PMOS-first podcasts that spends real time on midlife, insulin resistance and the perimenopause overlap. search 'perimenopause' or 'midlife'
Dr Mark Hyman
Broad metabolic-health show with useful episodes on insulin resistance, midlife weight and the metabolic side of the PMOS story. search 'PCOS', 'insulin resistance' or 'metabolic health'
Max Lugavere
Metabolic and brain-health episodes worth the time when PMOS-plus-perimenopause has made you newly interested in insulin and inflammation. search 'insulin resistance' or 'women's health'
Dr Felice Gersh
The most direct patient-facing book on this exact overlap, from a gynecologist who has spent her career on PMOS and midlife metabolic care.
Dr Mary Claire Haver
The wider menopause playbook, essential for framing MHT and metabolic decisions when PMOS is in the mix.
Dr Peter Attia
Not a PMOS book. But the cardiometabolic framework in Outlive is the one PMOS people most need in midlife — strength, apoB, glucose, sleep.
Deep-links to the shelf inside our research library.
U.S. Department of Veterans Affairs and Department of Defense · August 2026
U.S. VA/DoD guidance published August 2026, based on evidence reviewed through June 2025; supports individualized care rather than replacing clinical judgment.
U.S. Department of Veterans Affairs and Department of Defense · August 2026
U.S. VA/DoD guidance published August 2026, based on evidence reviewed through June 2025; supports individualized care rather than replacing clinical judgment.
This is a starting point, not a diagnosis or treatment plan.
Suggest a correction / Suggest a guide